Brinzolamide is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. It is available as ophthalmic suspension. MedsAcross supplies Brinzolamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
AZOPT is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. AZOPT is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
Source: US FDA prescribing information
Carbonic anhydrase is an enzyme found in many tissues of the body, including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II, found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in IOP. AZOPT contains brinzolamide, an inhibitor of carbonic anhydrase II. Following topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated IOP.
Source: US FDA prescribing information
The recommended dose is one drop of AZOPT in the affected eye(s) 3 times daily. Shake well before use. AZOPT may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 10 minutes apart. • Instill one drop in the affected eye(s) 3 times daily. • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 10 minutes apart.
Source: US FDA prescribing information
AZOPT is contraindicated in patients who are hypersensitive to any component of this product. Hypersensitivity to any component of this product.
Source: US FDA prescribing information
• Sulfonamide hypersensitivity reactions. • Corneal edema may occur in patients with low endothelial cell counts. Sulfonamide Hypersensitivity Reactions AZOPT is a sulfonamide and although administered topically, it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of AZOPT. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation immediately.
Source: US FDA prescribing information
Most common adverse reactions (incidence 5% to 10%) are blurred vision and bitter, sour, or unusual taste.
Source: US FDA prescribing information
• There is a potential additive effect of the known systemic effects of carbonic anhydrase inhibition in patients receiving both oral and topical carbonic anhydrase inhibitors. • Rare instances of acid-base alterations have occurred with high-dose salicylate therapy.
Source: US FDA prescribing information
Store AZOPT at 4°C to 30°C (39°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Brinzolamide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Brinzolamide 10 mg/mL ophthalmic suspensionOphthalmicGeneric name | — | US FDA | Available on request |
| Azopt 10 mg/mL ophthalmic suspensionOphthalmic | Sandoz | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Brinzolamide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Brinzolamide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Brinzolamide, including Azopt.
Yes. The US FDA first approved Brinzolamide on 1 April 1998, according to Drugs@FDA.
Yes. Brinzolamide has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Brinzolamide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Brinzolamide is classified under ATC code S01EC04 (Brinzolamide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.